Compugen (NASDAQ:CGEN) Share Price Crosses Above 200-Day Moving Average – Should You Sell?

Shares of Compugen Ltd. (NASDAQ:CGEN) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.28 and traded as high as $2.50. Compugen shares last traded at $2.41, with a volume of 279,975 shares traded.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of Compugen in a research note on Tuesday, August 4th. Wall Street Zen lowered Compugen from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Leerink Partners lowered their price target on Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, May 21st. Finally, Weiss Ratings upgraded Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Compugen has a consensus rating of “Buy” and a consensus price target of $5.00.

Compugen Stock Down 3.6%

The firm’s 50 day simple moving average is $2.24 and its 200-day simple moving average is $2.28. The company has a market capitalization of $227.87 million, a PE ratio of 6.34 and a beta of 2.77.

Compugen (NASDAQ:CGEN) last issued its earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Compugen had a net margin of 47.56% and a return on equity of 42.57%. The business had revenue of $2.60 million for the quarter, compared to the consensus estimate of $1.28 million. During the same quarter last year, the firm posted ($0.08) EPS. As a group, sell-side analysts anticipate that Compugen Ltd. will post -0.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. acquired a new stake in shares of Compugen in the second quarter valued at about $56,000. Jane Street Group LLC lifted its position in Compugen by 1,077.0% during the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after acquiring an additional 359,785 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in Compugen by 346.0% in the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 34,045 shares during the period. Two Sigma Investments LP boosted its holdings in Compugen by 10.6% in the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 18,929 shares during the period. Finally, Raymond James Financial Inc. grew its position in Compugen by 51.0% in the third quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 34,215 shares in the last quarter. Institutional investors and hedge funds own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.